Roundup Cancer Settlement Under Fire as Supreme Court Ruling Looms

The Roundup cancer settlement has hit a major roadblock as lawyers tied to a high-profile Supreme Court case work to disrupt a proposed $7.25 billion class-action agreement with Monsanto. The deal, which aims to resolve thousands of cancer-related lawsuits linked to the popular weed killer, is now caught in a tense legal tug-of-war that could reshape the future of product liability claims in the United States.

A High-Stakes Battle Over Compensation

At the heart of the dispute is whether people who say Roundup made them sick will be fairly compensated — or whether the proposed settlement primarily serves to protect Monsanto and its parent company, Bayer.

Attorneys challenging the agreement have labelled it a “sweetheart deal,” arguing that it shortchanges cancer victims while shielding the company from substantial future liability. They claim the structure of the deal favors corporate interests over the rights of those affected.

To strengthen their challenge, the lawyers filed paperwork on May 22 seeking to move the case from state court to federal court. Such a transfer could place it in front of a federal judge who has openly criticized the proposed agreement.

In their filing, the attorneys went so far as to say the class action was created not to genuinely pursue claims, but as a strategy to “launder a liability-management scheme” through the courts.

What the Filing Could Mean

This legal maneuver is widely expected to delay a critical deadline of June 4, by which affected individuals must decide whether to accept the settlement or opt out. The delay also raises the likelihood that the deal won’t be finalized before the U.S. Supreme Court announces its long-awaited decision.

The court’s ruling — expected by early July — could either allow or block thousands of lawsuits accusing Monsanto of failing to include a cancer warning label on Roundup.

Why the Supreme Court Case Matters

In April, the Supreme Court heard oral arguments on whether Roundup users who developed cancer have the right to sue under state laws governing dangerous products. The justices appeared divided, with no clear indication of how the case might be decided.

This uncertainty places Roundup users in a difficult position. They must choose whether to accept a guaranteed but limited settlement now, or wait for a court ruling that could either strengthen or eliminate their legal options.

Bayer’s Strategy to Limit Future Lawsuits

Bayer, the German pharmaceutical and agricultural giant, acquired Monsanto in 2018 and inherited a wave of legal challenges related to Roundup. The company has been working on multiple fronts to manage and contain its liability, including:

Defending Roundup’s safety in court

Negotiating large settlements like the current one

Lobbying for legislation that would offer legal protection from cancer-related lawsuits

The proposed $7.25 billion deal is seen as central to Bayer’s strategy. If finalized, it could resolve a significant portion of existing claims and reduce the company’s exposure to future litigation.

Lawyers Argue the Deal Is Rushed and Unfair

Ashley Keller, who represents the central plaintiff in the Supreme Court case as well as several other litigants, criticized the rapid timeline of the settlement. According to him, the tight deadlines appear designed to create maximum pressure on victims to settle quickly, before the Supreme Court issues its ruling.

Keller argued that the settlement effectively strips the legal rights of tens of thousands of cancer patients and was pushed through state court at a pace that disadvantages claimants.

He called the move strategic — aimed at forcing people to make rushed decisions amid legal uncertainty.

The Other Side: Why Some Lawyers Support the Settlement

Not everyone agrees with the criticism. Attorney Christopher Seeger, who helped broker the agreement, dismissed Keller’s effort as a delay tactic and urged the court to reject it.

Seeger argued that the Supreme Court case, known as Durnell, has the potential to eliminate failure-to-warn claims entirely, leaving many victims without any path to compensation. He also pointed to the possibility of Bayer filing for bankruptcy, which could leave even more claimants empty-handed.

According to him, the $7.25 billion settlement represents the most reliable opportunity for cancer victims — many of whom have waited more than ten years for resolution — to receive guaranteed financial relief.

Bayer Pushes to Keep the Case in State Court

A spokesperson for Bayer confirmed that the company will resist any attempts to move the case to federal court. Since most claims have been filed at the state level, keeping the case in state court is seen as crucial to maintaining the settlement’s current structure.

The Role of the EPA

Adding another layer of complexity, the Environmental Protection Agency has not classified Roundup as a cancer-causing product. Federal regulators currently do not require the product to carry a cancer warning label.

This regulatory stance is now central to the Supreme Court case. The justices are determining whether the EPA’s position blocks Roundup users from suing under state laws that govern hazardous consumer products.

If the court rules in Bayer’s favor, thousands of lawsuits could be dismissed. A ruling against Bayer, on the other hand, could open the door to many more legal challenges.

What Comes Next

With the Supreme Court ruling expected within weeks, the next month will be pivotal for everyone involved — from cancer patients seeking justice to Bayer’s shareholders watching the company’s legal future unfold.

Key issues to watch include:

Whether the case is moved to federal court

How the June 4 settlement deadline plays out

The Supreme Court’s decision on failure-to-warn claims

Possible new federal legislation shielding Bayer

For now, Roundup users face a difficult choice between accepting an imperfect settlement or holding out hope that the highest court in the country will side with them. The outcome may not just affect Bayer — it could redefine how Americans hold corporations accountable for the products they sell.